Guangdong Dtech Technology
301377
Ganzhou Yihao New Materials
301176
Shenzhen Edadoc Technology
301366
Suzhou SLAC Precision Equipment
300382
Shenzhen Q&D Circuits
301628
CN Stock MarketDetailed Quotes
688117 ChengDu Sheng Nuo Biotec
- 24.08
- +0.32+1.35%
Trading Jan 9 09:48 CST
2.71BMarket Cap29.26P/E (TTM)
24.10High23.50Low3.15KlotVolume23.69Open23.76Pre Close7.54MTurnover0.28%Turnover Ratio38.47P/E (Static)112.42MShares36.9852wk High2.93P/B2.71BFloat Cap16.2652wk Low28.51Limit Up112.42MShs Float57.26Historical High19.01Limit Down2.53%Amplitude14.38Historical Low0.20Dividend TTM23.94Avg Price1.09KlotAsk0.83%Div YieldTTM100Lot Size1.60KlotBid
ChengDu Sheng Nuo Biotec News
The competition is fierce! Musk once said that "Tirzepatide", which is more effective than semaglutide, will be launched in China. Who will dominate the weight loss drug market in 2025?
① Today, Eli Lilly and Co announced the official launch of tirzepatide in China, covering both type 2 diabetes and weight loss, and it is already available on some online platforms; ② Musk has claimed that tirzepatide is better than semaglutide, while the market is more focused on the pricing of tirzepatide and whether it will be included in medical insurance; ③ The competition in the GLP-1 sector will become even more intense in 2025, with Jiangsu Hengrui Pharmaceuticals, INNOVENT BIO, and Gan & Lee Pharmaceuticals receiving widespread attention.
Shengnuo Bio (688117.SH): The project for Teirbo peptide Active Pharmaceutical Ingredient and formulation is currently in the pharmaceutical research stage.
Gelonghui reported on December 26 that Shengnuo Bio (688117.SH) stated on the investor interaction platform that the Active Pharmaceutical Ingredient and injection project for Semaglutide is currently in the pharmaceutical research stage, and the Active Pharmaceutical Ingredient for Semaglutide has been filed with the USA FDA. The project for the Active Pharmaceutical Ingredient and formulation of Teriparatide is also currently in the pharmaceutical research stage.
Shengnuo Biotechnology (688117.SH): Lepu Medical Technology has cumulatively reduced its shareholding by 0.7912%.
On December 26, Gelonghui reported that Shengnuo Biology (688117.SH) announced that the company recently received a notification letter from Lepu Medical Technology regarding the results of shareholding reduction. As of the date of this announcement, Lepu Medical Technology has cumulatively reduced its shareholding by 889,445 shares through centralized bidding, accounting for 0.7912% of the company's total share capital. After the reduction, Lepu Medical Technology holds 5,272,000 shares of the company, accounting for 4.6896% of the company's total share capital, and this shareholding reduction plan has reached its expiration.
Concept mining | Simgeglutide weight loss drug officially launched in China, multiple e-commerce platforms have gone online
The market has broad prospects
Shengnuo Biology (688117): Rapid growth in Q3 performance, substantial order landing to boost medium and long-term development.
Q3 performance grew rapidly, with the three core sub-businesses showing overall stable development in 2024 Q1-3. The company achieved revenue of 0.338 billion yuan, a year-on-year increase of 16.00%; net income attributable to shareholders was 56.95 million yuan, a year-on-year increase of 63.66.
Shengnuo Biology (688117): A pioneer in the peptide field, overseas layout to create long-term growth space.
The company released the Q3 financial report for 2024, with a revenue of 0.139 billion yuan, an increase of 18.32% year-on-year, and a net income attributable to non-controlling interests of 34.53 million yuan, an increase of 144.80% year-on-year. Revenue for the first three quarters of 2024 reached 3 billion yuan.
Shengnuo Biotech: Third Quarter Report 2024
Third Quarter Report 2024
ChengDu ShengNuo Biotec's Nine-Month Profit Seen to Surge Up to 76%
VOLUNTARY DISCLOSURE ANNOUNCEMENT FOR THE FIRST THREE QUARTERS OF 2024
Another one! Peptide products drive 'hot' performance, Sanuo Biological's net profit for the first three quarters is expected to increase by 76%.
①Peptide active pharmaceutical ingredients and formulation products are selling well, driving Shen Nuo Biotech's net income in the first three quarters to reach as high as 61.1987 million yuan, with the highest year-on-year increase of 75.88%. ②In September of this year, Shen Nuo Biotech signed a GLP-1 peptide active pharmaceutical ingredient supply contract worth up to 0.35 billion yuan, with a performance period until December 31, 2025.
Express News | Shengnuo Biotechnology: It is expected that the net income in the first three quarters will increase by 43.90% to 75.88% year-on-year.
Express News | Shengnuo Biotechnology: There is still uncertainty whether the trade can be finally completed.
Shengnuo Biotechnology (688117): Capacity expansion in the pipeline, poised for rapid development. Peptide drugs are experiencing rapid growth.
Recommendation logic: 1) In 2024, global peptide drug sales reached $87.6 billion, GLP-1 drugs are booming, and it is expected that by 2030, china's peptide active pharmaceutical ingredient market size will reach 65.25 billion yuan; 2) Company's production capacity landed.
Express News | Star market closing: SSE Science and Technology Innovation Board 50 Index fell by 0.48%, medical instruments and biopharmaceutical sectors declined.
Stock market volatility | With the brokerage's positive outlook, Shengnuo Biotechnology rose more than 9% in the afternoon.
Gelonghui on September 19th: Yesterday, Sanuo Biotech (688117.SH), which fell more than 9%, surged to over 9% in the afternoon, and is now trading at 29.7 yuan, with a total market value of 3.33 billion yuan. The latest report from China Post Securities points out that the company has frequent bullish news, and its medium to long-term development is positive. The climbing production capacity of the company's GLP-1 active pharmaceutical ingredient, combined with the release of substantial orders, is expected to contribute substantial performance. In early September, the company proposed to invest 30 million yuan to subscribe for 22.78% equity of the target company in Tanzania, which is beneficial for further expanding the international layout of the company's peptide products. Maintain the recommendation and give a “buy” rating.
San Nuo Biology (688117): The new signed orders are expected to significantly increase the company's performance, and the long-term development continues to improve.
Event: On September 17th, Sanuo Biotech released an announcement on the signing of a significant contract for daily operations by its wholly-owned subsidiary. Sanuo Pharmaceutical, a wholly-owned subsidiary of the company, recently signed a Product Purchase Contract with a certain client to supply the contract party.
Express News | Star Market Market Summary: Biopharmaceuticals and lithium battery sectors performed poorly, while semiconductor sector had mixed gains and losses.
ChengDu ShengNuo Biotec Unit Signs Up to 350 Million-Yuan Peptide Supply Contract
Sanon Bio (688117.SH): Subsidiary signs GLP-1 peptide active pharmaceutical ingredient sales contract not exceeding 0.35 billion yuan
Shengnuo Biotech (688117.SH) announced that Chengdu Shengnuo Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the company (“Shengnuo...